A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Gynecologic Oncology Group
ClinicalTrials.gov Identifier:
NCT00939809
First received: July 14, 2009
Last updated: February 27, 2015
Last verified: February 2015
Results First Received: February 3, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Fallopian Tube Carcinoma
Malignant Ovarian Mixed Epithelial Tumor
Ovarian Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Undifferentiated Ovarian Carcinoma
Interventions: Biological: Urokinase-Derived Peptide A6
Other: Laboratory Biomarker Analysis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study was activated on 7/6/2009 and closed to accrual on 1/4/2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
A6 (Subcutaneous) 300 mg A6 Subcutaneously daily (2 injections of 150 mg) (cycle = 28 days) until disease progression or adverse effects prohibit further therapy

Participant Flow:   Overall Study
    A6 (Subcutaneous)  
STARTED     31  
COMPLETED     28 [1]
NOT COMPLETED     3  
Adverse Event                 2  
Death                 1  
[1] Patients treated until disease progression; completed defined as off treatment due to progression.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
A6 (Subcutaneous) 300 mg A6 Subcutaneously daily (2 injections of 150 mg) (cycle = 28 days) until disease progression or adverse effects prohibit further therapy

Baseline Measures
    A6 (Subcutaneous)  
Number of Participants  
[units: participants]
  31  
Age, Customized  
[units: participants]
 
40-49 years     1  
50-59 years     11  
60-69 years     17  
70-79 years     2  
Gender  
[units: participants]
 
Female     31  
Male     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression-free Survival at 6 Months   [ Time Frame: Scans to assess progression were done every other cycle for the first 6 months. ]

2.  Primary:   Tumor Response   [ Time Frame: Scans to assess response were done every other cycle for the first 6 months; every three months thereafter; and at any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease or rising serum tumor marker levels. ]

3.  Secondary:   Progression-free Survival   [ Time Frame: scans to assess response were done every other cycle for the first 6 months; every three months thereafter; and at any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease or rising serum tumor marker levels. ]

4.  Secondary:   Overall Survival   [ Time Frame: Every other cycle, up to 5 years ]

5.  Secondary:   Biomarkers of Drug Effect on Peripheral Blood Mononuclear Cells (PBMCs)   [ Time Frame: Day 1 prior to dosing; Day 2 prior to dosing and 4-hour post dosing; Day 8 prior to dosing. ]

6.  Primary:   Frequency and Severity of Adverse Events as Assessed by CTCAE v3.0   [ Time Frame: Every cycle during treatment ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Note: due to the limited activity of this agent, it was decided not to expend resources assaying the PBMCs.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Jessalyn Reboy
Organization: Gynecologic Oncology Group Statistical and Data Center
phone: 716-845-7738
e-mail: reboyj@nrgoncology.org



Responsible Party: Gynecologic Oncology Group
ClinicalTrials.gov Identifier: NCT00939809     History of Changes
Other Study ID Numbers: GOG-0170N
NCI-2011-01927 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CDR0000644399
GOG-0170N ( Other Identifier: Gynecologic Oncology Group )
GOG-0170N ( Other Identifier: CTEP )
U10CA027469 ( US NIH Grant/Contract Award Number )
Study First Received: July 14, 2009
Results First Received: February 3, 2014
Last Updated: February 27, 2015
Health Authority: United States: Institutional Review Board